Faron Pharmaceuticals Oy
("Faron" or "Company")

Update to Faron's Financial Calendar for 2024

Company announcement February 27, 2024 at 1:00 p.m. EST / 6:00 p.m. GMT / 8:00 p.m. EET

TURKU, FINLAND / BOSTON, MA - February 27, 2024 - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers and inflammation via precision immunotherapy, today announces an update to its financial reporting calendar for 2023, further to the to the announcement on December 22, 2023.

The Company's financial statement release for the full year 2023 and Annual Report 2023, including financial statements for the full year, will now be published on March 14, 2024, at 2:00 a.m. EST / 07:00 a.m. GMT / 09:00 a.m. EET, rather than on Thursday, February 29, 2024, as had been previously communicated.

The publication date of Tuesday, August 27, 2024, for Faron's half-year financial report for the period January 1 to June 30, 2023, remains unchanged, as does the date for the Company's annual general meeting, which is planned to be held on Friday, March 22, 2024.

A separate stock exchange notice will be issued by Faron's board of directors to convene the meeting.

Full Year Results Virtual Briefing

Following publication of Faron's financial statement release for the full year 2023 on March 14, 2024, Dr. Markku Jalkanen, Chief Executive Officer, and James O'Brien, Chief Financial Officer, will host a virtual briefing and Q&A session for analysts on the day at 3:00 p.m. EET / 1:00 p.m. GMT. Presentation link https://faron.videosync.fi/q4-2023

The full year results press release for 2023, presentation, virtual briefing webcast details, and Annual Report 2023 will be made available at www.faron.com/investors. A replay of the analyst briefing will be made available shortly afterwards.

For more details about the analyst briefing, please contact Faron@consilium-comms.com.

For more information please contact:

Investor Contact

LifeSci Advisors

Daniel Ferry

Managing Director

daniel@lifesciadvisors.com

+1 (617) 430-7576

ICR Consilium

Mary-Jane Elliott, David Daley, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: faron@consilium-comms.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments treatments and as a monotherapy in last line solid cancers. Further information is available at www.faron.com.